#1 Clinical Trials Search in Europe

Izokibep

Izokibep is an innovative drug currently being studied in clinical trials for the treatment of several inflammatory conditions. This potent and selective inhibitor of interleukin-17A (IL-17A) is showing promise in addressing diseases such as hidradenitis suppurativa, psoriatic arthritis, and non-infectious uveitis. The ongoing trials aim to evaluate the efficacy, safety, and potential benefits of izokibep for patients suffering from these challenging conditions.

Table of Contents

What is IZOKIBEP?

IZOKIBEP is a new medication being developed to treat various autoimmune diseases. It is also known by its research name ABY-035[5]. IZOKIBEP is classified as a biologic drug, which means it is made from living organisms or contains components of living organisms. This type of medication is designed to target specific parts of the immune system[1][2].

How Does IZOKIBEP Work?

IZOKIBEP works by targeting a specific part of the immune system called interleukin-17A (IL-17A). IL-17A is a protein that plays a role in inflammation, which is the body’s response to injury or infection. In some autoimmune diseases, there is too much IL-17A, leading to excessive inflammation and tissue damage[1][2].

IZOKIBEP is described as a potent and selective inhibitor of IL-17A. This means it strongly and specifically blocks the action of IL-17A, potentially reducing inflammation and helping to control the symptoms of various autoimmune diseases[3].

What Conditions Does IZOKIBEP Treat?

IZOKIBEP is being studied for several autoimmune conditions, including:

  • Hidradenitis Suppurativa (HS): A painful, long-term skin condition that causes abscesses and scarring on the skin[1][4]
  • Psoriatic Arthritis (PsA): A type of inflammatory arthritis that affects some people with psoriasis[2]
  • Non-infectious Uveitis: Inflammation of the middle layer of the eye, which is not caused by an infection[3][5]

How is IZOKIBEP Administered?

IZOKIBEP is given as a subcutaneous injection. This means it is injected just under the skin. In most of the clinical trials, patients receive the medication either once a week or once every two weeks[1][2][3].

Current Clinical Trials

IZOKIBEP is currently being studied in several clinical trials:

  • A Phase 2b study for Hidradenitis Suppurativa[1]
  • A Phase 2b/3 study for Psoriatic Arthritis[2]
  • A Phase 2b study for Non-infectious Uveitis[3]
  • A Phase 3 study for Hidradenitis Suppurativa[4]
  • A Phase 2 study for Non-infectious Uveitis (called the LINNAEA trial)[5]

These trials are designed to test how well IZOKIBEP works and how safe it is for patients with these conditions.

Potential Benefits of IZOKIBEP

The potential benefits of IZOKIBEP are being studied in the ongoing clinical trials. Researchers are looking at several outcomes, including:

  • Improvement in symptoms of Hidradenitis Suppurativa, measured by a scale called HiSCR (Hidradenitis Suppurativa Clinical Response)[1][4]
  • Reduction in joint pain and swelling in Psoriatic Arthritis, measured by scales like ACR (American College of Rheumatology) response[2]
  • Improvement in eye inflammation in Uveitis, measured by factors like visual acuity and retinal thickness[3][5]
  • Improvement in quality of life for patients with these conditions[2][4]

Possible Side Effects and Safety Considerations

As with all medications, IZOKIBEP may cause side effects. The ongoing clinical trials are carefully monitoring for any adverse events. Some areas of special interest include:

  • Infections, including candida infections
  • Inflammatory bowel disease
  • Cardiovascular and cerebrovascular events
  • Changes in blood cell counts (cytopenias)
  • Allergic reactions[1][2][3]

It’s important to note that IZOKIBEP is still in the testing phase, and more information about its safety and effectiveness will become available as the clinical trials progress. Patients interested in this treatment should discuss it with their healthcare provider and consider participating in clinical trials if appropriate.

Condition Trial Phase Primary Outcome Administration Key Features
Hidradenitis Suppurativa Phase 2b/3 HiSCR75 at Week 16 Subcutaneous injection, weekly or every other week Includes placebo-controlled groups; evaluates efficacy in moderate to severe HS
Psoriatic Arthritis Phase 2b/3 ACR50 at Week 16 Subcutaneous injection, weekly Multiple dosing groups; assesses various aspects of disease activity and quality of life
Non-infectious Uveitis Phase 2b Time to treatment failure Subcutaneous injection, weekly Focuses on intermediate, posterior, or pan-uveitis; measures changes in visual acuity and retinal thickness

FAQ

  • What is Izokibep and how does it work? Izokibep is a biologic drug that acts as a potent and selective inhibitor of interleukin-17A (IL-17A). It is a small protein molecule that binds with high affinity to IL-17A, which is involved in inflammatory processes. By inhibiting IL-17A, izokibep aims to reduce inflammation in various conditions.
  • What conditions is Izokibep being studied for in clinical trials? Izokibep is currently being investigated in clinical trials for several inflammatory conditions, including hidradenitis suppurativa, psoriatic arthritis, and non-infectious uveitis (intermediate, posterior, or pan-uveitis).
  • How is Izokibep administered in these clinical trials? In the clinical trials, izokibep is administered as a subcutaneous (under the skin) injection. The frequency of administration varies depending on the study, but it is typically given either weekly or every other week.
  • What are some of the primary outcomes being measured in these trials? The primary outcomes vary depending on the condition being studied. For hidradenitis suppurativa, researchers are looking at the percentage of participants achieving HiSCR75 (Hidradenitis Suppurativa Clinical Response 75). In psoriatic arthritis, they're measuring the proportion of subjects achieving ACR50 (50% improvement in American College of Rheumatology criteria). For uveitis, they're assessing the time to treatment failure and the proportion of subjects achieving disease quiescence.
  • Are there any known side effects of Izokibep based on these trials? While the full safety profile is still being evaluated, the trials are monitoring for treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and events of special interest. These may include infections, changes in laboratory values, and other potential side effects. However, specific details about side effects are not provided in the given trial information.

Ongoing Clinical Trials on Izokibep

  • Study on Izokibep for Patients with Non-infectious Uveitis

    Not recruiting

    1
    Investigated drugs:
    Austria Czechia France Germany Italy Spain

  • Study on Izokibep for Patients with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    1 1
    Investigated drugs:
    France Germany Hungary Poland Spain

  • Study on Izokibep for Improving Symptoms in Patients with Active Psoriatic Arthritis

    Not recruiting

    1 1
    Investigated drugs:
    Bulgaria Czechia Germany Hungary Poland Spain

Glossary

  • Interleukin-17A (IL-17A): A type of protein involved in immune responses and inflammation. Izokibep works by inhibiting this protein to reduce inflammation in various conditions.
  • Hidradenitis Suppurativa (HS): A chronic skin condition characterized by painful, inflamed lesions in areas where skin rubs together, such as the armpits, groin, and under the breasts.
  • Psoriatic Arthritis: A type of inflammatory arthritis that affects some people with psoriasis, causing joint pain, stiffness, and swelling.
  • Uveitis: Inflammation of the uvea, the middle layer of the eye. Non-infectious uveitis refers to cases not caused by infection.
  • HiSCR75: Hidradenitis Suppurativa Clinical Response 75, a measure of improvement in hidradenitis suppurativa symptoms.
  • ACR50: American College of Rheumatology 50% improvement criteria, used to measure response to treatment in arthritis.
  • Subcutaneous (SC): A method of drug administration where the medication is injected just under the skin.
  • Treatment-emergent Adverse Events (TEAEs): Side effects or undesirable experiences that occur after starting a treatment in a clinical trial.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a drug against no treatment.
  • Double-blind: A study design where neither the participants nor the researchers know who is receiving the actual treatment or placebo.

References